Y-mAbs cuts 35% of staff; Genen­tech re-ups Nim­ble deal; Lan­dos shifts fo­cus; and more

A month af­ter the FDA re­ject­ed its neu­rob­las­toma drug, the biotech Y-mabs said it will cut 35% of its work­force to save cash and fo­cus on com­mer­cial­iz­ing its lone ap­proved prod­uct, Danyelza.

The FDA re­ject­ed its drug om­bur­tam­ab on Dec. 2, based on ques­tions about the com­pa­ny’s clin­i­cal tri­al and af­ter an ad­vi­so­ry com­mit­tee vot­ed 16-0 against rec­om­mend­ing the drug. The cuts will re­duce op­er­at­ing ex­pens­es by 28%, and give Y-mabs enough cash to get through the first quar­ter of 2026.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.